IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v28y2010i5p395-409.html
   My bibliography  Save this article

Direct and Indirect Costs of Non-Vertebral Fracture Patients with Osteoporosis in the US

Author

Listed:
  • Crystal Pike
  • Howard Birnbaum
  • Matt Schiller
  • Hari Sharma
  • Russel Burge
  • Eric Edgell

Abstract

Background: Osteoporosis is a condition marked by low bone mineral density and the deterioration of bone tissue. One of the main clinical and economic consequences of osteoporosis is skeletal fractures. Objective: To assess the healthcare and work loss costs of US patients with non-vertebral (NV) osteoporotic fractures. Methods: Privately insured (aged 18–64 years) and Medicare (aged ≥65 years) patients with osteoporosis (ICD-9-CM code: 733.0x) were identified during 1999–2006 using two claims databases. Patients with an NV fracture (femur, pelvis, lower leg, upper arm, forearm, rib or hip) were matched randomly on age, sex, employment status and geographic region to controls with osteoporosis and no fractures. Patient characteristics and annual healthcare costs were assessed over the year following the index fracture for privately insured (n=4764) and Medicare (n=48 742) beneficiaries (Medicare drug costs were estimated using multivariable models). Indirect (i.e. work loss) costs were calculated for a subset of privately insured, employed patients with available disability data (n=1148). All costs were reported in $US, year 2006 values. Results: In Medicare, mean incremental healthcare costs per NV fracture patient were $US13 387 ($US22 466 vs $US9079; p > 0.05). The most expensive patients had index fractures of the hip, multiple sites and femur (incremental costs of $US25 519, $US20 137 and $US19 403, respectively). Patients with NV non-hip (NVNH) fractures had incremental healthcare costs of $US7868 per patient ($US16 704 vs $US8836; p > 0.05). Aggregate annual incremental healthcare costs of NVNH patients in the Medicare research sample (n=35 933) were $US282.7 million compared with $US204.1 million for hip fracture patients (n=7997). Among the privately insured, mean incremental healthcare costs per NV fracture patient were $US5961 ($US11 636 vs $US5675; p > 0.05). The most expensive patients had index fractures of the hip, multiple sites and pelvis (incremental costs of $US13 801, $US9642 and $US8164, respectively). Annual incremental healthcare costs per NVNH patient were $US5381 ($US11 090 vs $US5709; p > 0.05). Aggregate annual incremental healthcare costs of NVNH patients in the privately insured sample (n=4478) were $US24.1 million compared with $US3.5 million for hip fracture patients (n=255). Mean incremental work loss costs per NV fracture employee were $US1956 ($US4349 vs $US2393; p > 0.05). Among patients with available disability data, work loss accounted for 29.5% of total costs per NV fracture employee. Conclusion: The cost burden of NV fracture patients to payers is substantial. Although hip fracture patients were more costly per patient in both Medicare and privately insured samples, NVNH fracture patients still had substantial incremental costs. Because NVNH patients accounted for a larger proportion of the fracture population, they were associated with greater aggregate incremental healthcare costs than hip fracture patients. Copyright Adis Data Information BV 2010

Suggested Citation

  • Crystal Pike & Howard Birnbaum & Matt Schiller & Hari Sharma & Russel Burge & Eric Edgell, 2010. "Direct and Indirect Costs of Non-Vertebral Fracture Patients with Osteoporosis in the US," PharmacoEconomics, Springer, vol. 28(5), pages 395-409, May.
  • Handle: RePEc:spr:pharme:v:28:y:2010:i:5:p:395-409
    DOI: 10.2165/11531040-000000000-00000
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/11531040-000000000-00000
    Download Restriction: Access to full text is restricted to subscribers.

    File URL: https://libkey.io/10.2165/11531040-000000000-00000?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Zethraeus, Niklas & Borgström, Fredrik & Johnell, Olof & Kanis, John & Önnby, Karin & Jönsson, Bengt, 2002. "Costs and quality of life associated with osteoporosis related fractures - Results from a Swedish survey," SSE/EFI Working Paper Series in Economics and Finance 512, Stockholm School of Economics.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Silke Andrich & Burkhard Haastert & Elke Neuhaus & Kathrin Neidert & Werner Arend & Christian Ohmann & Jürgen Grebe & Andreas Vogt & Pascal Jungbluth & Grit Rösler & Joachim Windolf & Andrea Icks, 2015. "Epidemiology of Pelvic Fractures in Germany: Considerably High Incidence Rates among Older People," PLOS ONE, Public Library of Science, vol. 10(9), pages 1-13, September.
    2. Hema N. Viswanathan & Jeffrey R. Curtis & Jingbo Yu & Jeffrey White & Bradley S. Stolshek & Claire Merinar & Akhila Balasubramanian & Joel D. Kallich & John L. Adams & Sally W. Wade, 2012. "Direct healthcare costs of osteoporosis-related fractures in managed care patients receiving pharmacological osteoporosis therapy," Applied Health Economics and Health Policy, Springer, vol. 10(3), pages 163-173, May.
    3. Sonya Sanderson & Scot Raab & Peggy Moch, 2012. "BMI and EAT-26, Predictors for Low BMD?," SAGE Open, , vol. 2(1), pages 21582440124, January.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Zethraeus, Niklas & Borgström, Fredrik & Jönsson, Bengt & Kanis, John, 2004. "A reassessment of the cost-effectiveness of hormone replacement therapy in Sweden – results based on the Women’s Health Initiative randomised controlled trial," SSE/EFI Working Paper Series in Economics and Finance 571, Stockholm School of Economics.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:28:y:2010:i:5:p:395-409. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.